BRAF and non-small cell lung carcinoma: Moreover, only one low-grade immune-related adverse event was observed during the course of immunotherapy.<h4>Conclusion</h4>Patients with advanced NSCLC and <i>BRAF</i> mutations who cannot tolerate targeted therapy are expected to benefit from immunotherapy.